Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news